Many features of how gene transcription occurs in human cells remain unclear, mainly because of a lack of quantitative approaches to follow genome transcription with nucleotide precision in vivo. Here we present a robust genome-wide approach for studying rna polymerase II (pol II)-mediated transcription in human cells at single-nucleotide resolution by native elongating transcript sequencing (net-seq). elongating rna polymerase and the associated nascent rna are prepared by cell fractionation, avoiding immunoprecipitation or rna labeling. the 3′ ends of nascent rnas are captured through barcode linker ligation and converted into a Dna sequencing library. the identity and abundance of the 3′ ends are determined by high-throughput sequencing, which reveals the exact genomic locations of pol II. Human net-seq can be applied to the study of the full spectrum of pol II transcriptional activities, including the production of unstable rnas and transcriptional pausing. By using the protocol described here, a net-seq library can be obtained from human cells in 5 d.
IntroDuctIon
Elucidating how genome transcription is regulated in human cells requires genomic tools that reveal the exact location of transcribing RNA polymerases. The application of genome-wide methods that map RNA Pol II density along genomes in vivo has uncovered new general features of gene transcription, and it has changed the view of how genomes are transcribed in living cells [1] [2] [3] . Originally, it was thought that the recruitment of Pol II to the gene promoter and transcription initiation were the major regulatory steps during RNA synthesis 4 . However, genomic methods that map Pol II occupancy in vivo have shown that Pol II is predominantly located in a region 50-100 nt downstream of the transcription start site (TSS) in the majority of active mammalian genes, indicating promoter-proximal pausing 2, 3, 5, 6 . These genome-wide studies provided strong evidence that transcription elongation by Pol II is a key regulatory step in RNA production. In addition, genomic approaches also found that Pol II transcription in the sense orientation is usually accompanied by divergent antisense transcription at the majority of promoters of active mammalian genes [7] [8] [9] . Genomewide Pol II profiling studies revealed that promoter-proximal pausing of Pol II in the sense direction typically co-occurs with promoter-proximal pausing in the upstream antisense orientation in mammalian cells, which uncovered new complexities of genome transcription 6, [10] [11] [12] [13] [14] .
Until now, two genome-wide strategies have mainly been applied to mapping RNA polymerase density across mammalian genomes, as described in more detail in the 'Comparison with other approaches' section below: chromatin immunoprecipitation (ChIP)-based approaches 5, [15] [16] [17] [18] [19] [20] and transcription run-on-based methods 8, 21, 22 . Here we provide a step-by-step protocol for NETseq, which is an alternative method for mapping Pol II genome transcription with single-nucleotide precision and DNA strand specificity in unperturbed human cells. Human NET-seq is a robust Pol II profiling approach that does not require any genetic modification or labeling of the nascent RNA, and its application to different human cell types is straightforward; we have successfully applied the NET-seq approach to four different human cell types, as described in detail in the following section.
Development and overview of human NET-seq
NET-seq allows RNA polymerase transcription elongation to be studied with single-nucleotide precision in vivo. The NET-seq methodology was originally developed for budding yeast grown to mid-log phase 23, 24 . In the original yeast NET-seq approach, native Pol II transcription elongation complexes were quantitatively purified by IP using a C-terminal 3× FLAG-tagged version of the Pol II subunit Rpb3 (refs. 23, 24) . A very similar approach was recently used to map the RNA polymerase density across the bacterial genome 25, 26 . Although the NET-seq strategy was recently applied to Drosophila S2 and Kc cells 27, 28 , a NET-seq method was not available for mammalian cells. To provide a simple and robust genomic tool for visualizing Pol II transcription with singlenucleotide precision in human cells, we developed a human NETseq approach 29 . Human NET-seq revealed new general aspects of Pol II transcription, including widespread transcriptional pausing across the expressed human genome and new promoter-proximal transcriptional activity in the antisense orientation 29 .
Human NET-seq is a quantitative genomic approach. This requires a strategy to quantitatively (>95% as determined by western blot analysis) purify transcriptionally engaged RNA polymerase from human cells, as well as an efficient sequencing library preparation method (Fig. 1) .
In contrast to the yeast NET-seq method, in which an epitopetagged version of Pol II is purified by IP 23, 24 , we have found that the most efficient and simple way to quantitatively purify transcribing Pol II from human cells is by cellular fractionation. Here we exploit the high degree of stability of the Pol II transcription elongation complex, which is very stable even in the presence of large amounts of salts, detergents and urea [30] [31] [32] [33] . Upon fractionation, the cytoplasm and the nucleoplasm are removed (eliminating the bulk of mature mRNA), and elongating Pol II associated with the nascent RNA is greatly enriched in the chromatin fraction ( Figs. 1 and 2) . Briefly, human cells are lysed in the presence of mild detergents. Nuclei are separated from the cytoplasm by centrifugation through a sucrose cushion. Next, nuclei are washed to remove cytoplasmic remnants. The nucleoplasm is separated from the chromatin in the presence of urea, salt and mild detergents. Urea removes chromatin-bound proteins, except the very stable elongating RNA polymerase and histone proteins 32, 34, 35 . As the histone proteins are not detached upon urea treatment, the native chromatin can be collected by low-speed centrifugation using a refrigerated benchtop centrifuge. No ultracentrifugation is required. The chromatin-associated nascent RNA is purified, and the remaining DNA is degraded by DNase treatment.
The cell fractionation approach described here is based on protocols published by the Schibler and Black laboratories 32, 34, 36 . However, the fractionation procedure has been modified and extensively optimized to ensure that: (i) More than 95% of elongating Pol II, together with the nascent RNA, is captured in the chromatin fraction. This was achieved by a systematic optimization of cell lysis conditions, as well as of the buffers and solutions used for subcellular fractionation.
(ii) Cross-contamination between the subcellular fractions is minimized. This was realized by optimizing buffer and washing conditions during subcellular fractionation. (iii) The risk of transcriptional run-on and RNA/protein degradation during sample preparation is reduced. This was accomplished by performing the cell fractionation in the presence of α-amanitin (a strong inhibitor of elongating Pol II (ref. 37)), RNase and protease inhibitors and by conducting all experimental steps on ice or at 4 °C. Furthermore, a fast and efficient cell lysis method is used, which leads to rapid depletion of the nuclear nucleotide triphosphate (NTP) pool and further reduces the risk of run-on transcription during cell fractionation.
Apart from its simplicity and robustness, other major advantages of this purification approach are that it avoids restarting Pol II in vitro to label and purify nascent RNA, and that it evades possible biases from epitope masking and cross-reactivity when antisera are used for Pol II purification. The 3′ ends of the purified nascent RNA are then converted into a DNA sequencing library (Fig. 1) . The human NET-seq library generation is based on the library preparation method that was originally 
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Step 105 and box 4: sequencing and data analysis α-Amanitin developed for budding yeast 23, 24 , but it includes two important modifications to minimize biases and to increase the efficiency by which the human nascent RNA is converted into a NET-seq library:
Barcode DNA linker ligation. In contrast to the original yeast NET-seq library preparation method 23, 24 , human NET-seq uses a barcoded DNA linker with a random hexameric sequence at the 5′ end ( Table 1) . The use of this new DNA linker pool has two main advantages. First, mispriming artifacts that can arise during reverse transcription (RT) are strongly reduced 29 . We observed that because of the length of human nascent RNA the RT primer anneals to stretches of complementarity within the nascent RNA that are as short as six nucleotides, leading to frequent mispriming events 29 . By ligating a DNA linker pool that possesses a random hexameric sequence at the 5′ end, mispriming events during RT are markedly decreased 29 . Second, the random hexameric sequence serves as a molecular barcode that allows PCR duplicates and residual mispriming RT events to be identified and bioinformatically removed 29 .
Depletion of abundant chromatin-associated mature RNAs. Specific depletion of the most abundant chromatin-associated • • mature RNAs increases the fraction of sequencing reads that originate from nascent Pol II transcripts 29 . Specific depletion is performed by subtractive hybridization using a set of 20 biotinylated DNA oligos ( Table 2 ) that anneal to the 3′ ends of the original mature RNA and are removed with streptavidin-coupled magnetic beads (Fig. 1) . The specific subtractive hybridization strategy described here is based on the tailored rRNA depletion protocol of the ribosome profiling approach 38 . Finally, the identity and the abundance of the 3′ ends of the original nascent RNA are determined by high-throughput single-end sequencing. This identifies the last nucleotide that was incorporated into the nascent RNA chain and thus the exact genomic position of the RNA polymerase active site. After these main experimental steps, NET-seq provides a quantitative measure of Pol II density across the human genome with single-nucleotide resolution.
Here we present a step-by-step protocol for performing NET-seq in cultured human cells, from cell lysis through to the quality control measures of the final NET-seq library (Fig. 1) . The human NET-seq protocol was originally applied to HeLa S3 and HEK293T cells 29 . We have since successfully performed NET-seq on two other human cell types (K562 and MOLT-4 cells; A.M., data not shown), suggesting that the technique is robust and that it works for different human cell types. The detailed description of the experimental steps from cell lysis to the quality control measures of the final NET-seq library will allow our colleagues to adapt this approach in their own laboratories.
Advantages and applications of human NET-seq
NET-seq can be applied to address a broad range of biological questions. The most basic applications of the NET-seq approach can be derived from its main attributes. NET-seq maps Pol II density DNA strand specifically, and therefore it can be used to investigate how transcriptional directionality (sense and antisense transcription) is regulated in vivo.
Because of the single-nucleotide resolution, the human NET-seq approach provides a quantitative measure of Pol II occupancy at each nucleotide that is transcribed. Prominent peaks of Pol II density at specific nucleotides or within narrow regions reveal pausing sites, which are locations at which Pol II is detected with a higher probability. Thus, NET-seq is a powerful approach for studying how transcriptional pausing is regulated in the promoter-proximal region, as well as taBle 1 | DNA and RNA oligos required for NET-seq library preparation (5′-3′).
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Barcode DNA linker /5rApp/(N) 6 CTGTAGGCACCATCAAT/3ddC oLSC007 (RT primer) /5Phos/ATCTCGTATGCCGTCTTCTGCTTG/iSp18/CACTCA/iSp18/TCCGACGATCATTGATGGTGCCTACAG oNTI231 (reverse primer) CAAGCAGAAGACGGCATACGA oLSC006 (sequencing primer) TCCGACGATCATTGATGGTGCCTACAG rna oligo oGAB11 (control oligo) agucacuuagcgauguacacugacugug throughout gene-body regions of genes. In addition, the high spatial resolution allows Pol II transcriptional activities (e.g., sense and different types of antisense transcription 29 ) that arise in close proximity to each other to be distinguished. Human NET-seq now provides the opportunity to investigate how these activities are co-regulated in normal cells and upon disease conditions or treatments. Furthermore, NET-seq captures the RNA as it is being produced, and human NET-seq has been shown to detect unstable RNA species 29 such as promoter upstream transcripts 7 and upstream antisense RNAs 39 , as well as enhancer-derived noncoding RNAs 40, 41 . Human NET-seq can therefore be used to study these transcripts before they are turned over by cellular RNA degradation pathways [42] [43] [44] . Standard RNA-seq methods mainly capture steady-state mRNA levels of fully processed mature RNAs and thus struggle to detect unstable transcripts.
Application of human NET-seq revealed strong Pol II pauses at the boundaries of exons that are retained during splicing but not at exons that are subsequently removed by the spliceosome 29 . This indicates that Pol II recognizes exons with different processing fates where Pol II slows down at exons that are retained in the final mRNA. The determinants of Pol II pausing at exon boundaries and how Pol II transcription and splicing are coupled in vivo remain to be determined. NET-seq will help elucidate these links, and it will shed new light on the regulatory mechanisms that underlie these fundamental biological processes.
Although the NET-seq approach has been established and optimized for the analysis of Pol II transcription, the adaptation of the protocol to the RNA Pol I and RNA Pol III transcriptional systems should be straightforward. Using the human NET-seq protocol described here, we detect Pol I and Pol III transcription 29 . However, the NET-seq library preparation may require further adaptations to study Pol I and Pol III transcription in an unbiased way. For example, the extended secondary structures in Pol I and Pol III transcripts may pose a problem for the RT reaction.
Limitations of human NET-seq
To fully comprehend the potential applications of NET-seq and to extract meaningful conclusions, it is important to be cognizant of its limitations. NET-seq reveals the exact position of Pol II by determining the 3′ ends of Pol II-associated nascent RNA. Although Pol II involved in elongation can be localized with NET-seq, the exact genomic positions of Pol II that is part of the preinitiation complex (PIC) at promoter regions cannot be mapped because PIC formation occurs before nascent RNA is produced. In addition, Pol II involved in transcription initiation around the TSS of genes cannot be mapped, because the synthesized nascent transcripts are too short to produce mappable sequencing reads; minimum read lengths of ~18 nt are required for unique mapping to the human reference genome.
Purification of transcriptionally engaged RNA polymerase will co-purify nascent RNA and RNA processing intermediates from splicing and 3′-end cleavage. Thus, the NET-seq signal at the last nucleotide of introns and exons can either be because of elongating Pol II or splicing intermediates. Similarly, it is not clear whether the NET-seq signal that is obtained at the polyadenylation (pA) site, where the transcript is cleaved and polyadenylated, relates to transcriptionally engaged Pol II or to a 3′-end processing intermediate. Therefore, NET-seq signals at these single-nucleotide positions are computationally removed by discarding the corresponding sequencing reads.
Purification of transcriptionally engaged Pol II will also co-purify some fully processed mature RNAs. Abundant noncoding mature 29 , some mature mRNAs are likely to be captured in the final NET-seq library. These mature mRNAs can be polyadenylated or nonpolyadenylated at their 3′ ends. As this protocol is designed to sequence the 3′ ends of RNAs, the polyadenylated transcripts are not a problem. First, the long polyadenylated tracks are technically challenging for RT reactions, PCRs and sequencing platforms to capture. Second, any sequencing reads that arise from polyadenylated mature RNAs do not align to the human reference genome because of polyadenine stretches, and they are removed bioinformatically. NET-seq reads that arise from nonpolyadenylated mature mRNAs align exactly to the pA sites corresponding to the pA site for the transcript (see the 'Experimental design' section for more information). The identification of this subset of mature mRNAs and the subsequent removal of the corresponding sequencing reads depends on the annotation of the pA sites, which has been strongly improved over the past years and comprehensive maps are available 12, 45 . For genes in which the pA site information is lacking, these mature mRNAs might introduce low levels of background signals. These unspecific signals are restricted to a few single-nucleotide positions. Therefore, with the focus by NETseq on 3′-end sequencing, we expect that these unspecific signals occur at a much lower level compared with background signals that are usually observed in IP-based genomic methods for which the unspecific pull-down of RNAs represents an inherent problem when the entire molecule is fragmented and sequenced. Our conclusion that mature mRNAs have negligible impact, if any, on NET-seq results is based on two experimental results. First, we performed human NET-seq upon conditions in which productive Pol II transcription elongation is blocked, by inhibiting the Cdk9 subunit of the positive transcription elongation factor b (P-TEFb) 29 . P-TEFb represents a key player in the release of promoter-proximally paused Pol II (refs. 46,47) . In agreement with previous studies 5, 39 , Cdk9 inhibition resulted in a genomewide loss of productive elongating Pol II in both sense and antisense orientation 29 , indicating that NET-seq quantitatively captures transcribing Pol II. If mature mRNAs were influencing the NET-seq signal, we would not expect a complete reduction in productive elongating Pol II levels upon 1 h of P-TEFb inhibition. Second, key observations of mammalian Pol II transcription made by human NET-seq, such as widespread promoter-proximal pausing and divergent transcription originating from bidirectional promoters, are consistent with observations by many laboratories using a broad range of genomic methods [5] [6] [7] [8] [9] 18, [48] [49] [50] . Nevertheless, mature RNAs are likely to introduce some background signal, which is important to consider when inspecting NET-seq data.
The human NET-seq strategy described here requires 1 × 10 7 cells as an input, and it therefore works best for cells that can be obtained in larger quantities. Current efforts aim to reduce the amount of cells that are required per NET-seq experiment.
Comparison with other approaches
Before the development of NET-seq, two main strategies existed to determine the genome-wide location of Pol II and to study gene transcription in vivo: Pol II ChIP and transcription run-on. The Proudfoot and Carmo-Fonseca laboratories 51 have also recently developed a variant of the NET-seq approach for mammalian cells, called mNET-seq.
Pol II ChIP. In this approach, chromatin is cross-linked and Pol II-bound DNA is purified by IP typically using antibodies directed against Pol II. The DNA is converted into a library that is either hybridized to microarrays (ChIP-chip 15, 16, [52] [53] [54] [55] [56] [57] [58] ) or applied to high-throughput sequencing (ChIP-seq 5, 17, 18 ). Although these approaches have revealed the genomic Pol II density in various model organisms, including yeast and humans, the spatial resolution is usually limited to >200 bp because of the fragmentation approaches typically used 59 . ChIP data usually suffer from high levels of background signals due to the unspecific pull-down of DNA that can arise from cross-reactive antibodies or the unspecific binding of DNA to beads used in IP experiments. Furthermore, these methods lack DNA strand specificity, and the transcriptional state of Pol II remains unclear. To clarify whether Pol II is transcriptionally engaged, ChIP methods need to be complemented by other approaches such as permanganate footprinting assays 60 . Recent improvements in the genomewide ChIP approach could greatly increase spatial resolution and decrease nonspecific background signals 19, 20 . Although these new ChIP approaches lack single-nucleotide resolution and DNA strand specificity, they provide an opportunity to determine the location of Pol II during preinitiation and initiation of transcription complementing NET-seq and transcription run-on data.
Transcription run-on. To date, two transcription run-on approaches have been developed to map genomic Pol II density: global run-on-sequencing (GRO-seq) 8 and precision nuclear run-on and sequencing (PRO-seq) 21, 22 . In both methods, transcription is halted and then restarted in vitro in the presence of modified nucleotides that enable the purification of nascent RNA. The purified nascent RNA is then converted into a DNA sequencing library and subjected to high-throughput sequencing. These methods provide a DNA strand-specific quantitative measure of transcriptionally engaged Pol II, and they have provided new insights into gene regulation in various model organisms, including human cells and Drosophila cells. Similarly to human NET-seq, GRO-seq and PRO-seq require nascent RNAs of a minimum length (at least ~18 nt) so that the corresponding sequencing reads can uniquely align to the human reference genome. Therefore, these methods do not provide any information about the localization of Pol II during preinitiation or transcription initiation. Furthermore, transcription runon-based methods are strongly dependent on an efficient restart of transcription under nonphysiological conditions; this process is sensitive to the experimental setup and the transcriptional status of Pol II (ref. 61) . The pool of Pol II enzymes that are recovering from transcriptional pauses in which the nascent RNA is misaligned in the polymerase active site cannot be restarted in vitro; these polymerases therefore escape detection by nuclear run-on-based methods 27 . Thus, comparison of transcription run-on data with NET-seq data that maps all Pol II-paused, recovering and not paused-enables the identification of where Pol II is in the process of pause recovery 27 . mNET-seq. mNET-seq uses IP to purify Pol II (and its different C-terminal domain (CTD)-phosphorylated forms) with the associated nascent RNA from HeLa cells 51 , and thus it is capable of mapping subpopulations of Pol II across the genome. The ability to analyze Pol II complexes in a phosphorylation-dependent manner comes with the known limitations of an IP experiment, such as cross-reactivity of antibodies and unspecific binding of RNAs to beads, which are likely to result in unspecific background signals. It also comes at the cost of additional procedural steps. mNET-seq requires that Pol II transcription complexes be released from the chromatin by a micrococcal nuclease (MNase) digest; this process is inefficient, and it may release a biased subset of transcriptionally engaged Pol II (ref. 51 ). Subsequently, the purified nascent RNA must be phosphorylated at its 5′ end before entering a sequencing library protocol. In contrast, the human NET-seq protocol quantitatively purifies human Pol II elongation complexes by cellular fractionation, and it uses an optimized library preparation method to reduce experimental biases (Fig. 1) .
Experimental design
Each experimental step of the protocol described in the PROCEDURE has been optimized, and we recommend always including controls to monitor the success of key steps before sequencing a NET-seq library ( Figs. 2 and 3 ). Below we describe the steps that need particular attention before adapting the human NET-seq methodology. It is important that each step of the library construction works with high efficiency so that the DNA sequencing library quantitatively reflects the original pool of nascent RNA molecules.
Cell fractionation and RNA purification. The cell fractionation approach used in this protocol has been optimized for an input of 1 × 10 7 cells. If more input is required, we recommend performing fractionation on parallel samples rather than increasing the amount of cells per sample. The use of more cells per sample reduces the cell lysis efficiency and increases the risk of crosscontamination between the different subcellular fractions.
To avoid run-on transcription, the fractionation is performed in the presence of α-amanitin, which is a very strong inhibitor of elongating Pol II (refs. 37,62) . Furthermore, all steps are performed on ice or at 4 °C. To avoid the risk of RNA and protein degradation, the fractionation is conducted in the presence of RNase and protease inhibitors.
For RNA purification, it is important to use the miRNeasy kit instead of the RNeasy kit (Qiagen) to minimize RNA size biases.
Quality controls for cell fractionation. Cell fractionation represents the first fundamental step of the human NET-seq approach, and monitoring its success is crucial before proceeding with the NET-seq library preparation. We recommend performing western blot analysis by probing the subcellular fractions with antibodies directed against the elongating form of Pol II. We suggest using the well-characterized antibodies directed against the CTD Ser2-(3E10) and CTD Ser5 (3E8)-phosphorylated forms of Pol II, which were originally developed in the laboratories of Eick and Kremmer 63 . Approximately ≥95% of elongating Pol II should be captured in the chromatin fraction (Fig. 2) .
When applying the cell fractionation approach to a new cell type, we also recommend performing the following control experiments. To check for potential cross-contamination between the subcellular fractions, we suggest probing the different fractions on a western blot with antibodies raised against subcellular marker proteins (chromatin fraction: FL-126 directed against histone 2B; nucleoplasmic fraction: C-18 raised against U1 snRNP70; cytoplasmic fraction: 6C5 recognizing GAPDH; please also see MATERIALS for more information). The cytoplasmic and nucleoplasmic protein markers should be absent from the chromatin fraction. In addition, the enrichment of nascent intron-containing RNAs in the chromatin fraction compared with the nucleoplasmic and cytoplasmic fractions can be monitored by subcellular RNA-seq or by RT coupled with quantitative realtime PCR (RT-qPCR) using specific primer pairs directed against intronic regions of the nascent RNA. We performed subcellular RNA-seq for HeLa S3 and HEK293T cells, revealing that introncontaining nascent RNA is greatly enriched in the chromatin fraction 29 . The quantity and quality of the purified RNA can be monitored using a NanoDrop spectrophotometer.
Barcode DNA linker ligation. Although other adapter and/or barcoding strategies can be used, we strongly recommend using the barcode DNA linker design described here and the truncated version of the T4 RNA ligase 2 (from New England BioLabs (NEB)) for NET-seq library construction. High-throughput sequencing requires libraries that contain specific sequences, such as a binding site for the sequencing primer. In the NET-seq protocol, the DNA linker provides the sequence in which the RT primer anneals, which in turn introduces the binding site for the sequencing primer. Human NET-seq uses a barcode DNA linker that is preadenylated, and which possesses a random hexameric sequence at its 5′ end ( Table 1) . The barcode DNA linker is ligated to the 3′-hydroxyl group of nascent RNA molecules by a truncated version of the T4 RNA ligase 2. This truncated enzyme cannot adenylate the 5′ ends of the RNA substrate, thus reducing background ligation. In addition, the DNA linker possesses a dideoxy cytosine at the 3′ end to prevent its extension by the reverse transcriptase during the first-strand cDNA synthesis. This keeps the RT directional, and it is important for the strand specificity of the NET-seq library.
RNA fragmentation. RNA fragmentation by partial alkaline hydrolysis should result in a homogeneous RNA pool, with most of the molecules in the range of 35-100 nt (Fig. 3a) . We have observed that the optimal fragmentation time can vary with different batches of alkaline fragmentation solution, with the preferred fragmentation time usually between 10 and 40 min. We recommend that the optimal RNA fragmentation time be determined for each new batch of fragmentation solution. Even when the same batch of fragmentation solution is used, we suggest validating the fragmentation time every 4 months to minimize the risk of overfragmentation or underfragmentation of the RNA pool, as well as to maximize the reproducibility of the human NET-seq data.
Specific depletion of highly abundant mature RNAs. Although the vast majority of fully spliced mature RNAs are removed with the cytoplasmic and nucleoplasmic fractions, some mature RNA species are present in the chromatin fraction. These RNAs include chromatin-associated mature RNAs, such as small nuclear RNAs (snRNAs), which are an integral part of spliceosomes. Although the fraction of chromatin-associated mature RNAs is further reduced by urea treatment during the separation of the chromatin from the nucleoplasm, some fully processed RNAs are not completely removed and are part of the final NET-seq library, as described in the 'Limitations of human NET-seq' section above. NET-seq reads that are due to abundant noncoding mature RNA species, such as spliceosomal-associated RNAs, markedly reduce the amount of informative sequencing data; therefore, it is preferable to remove them before sequencing. Sequencing of our first NET-seq libraries generated from HeLa S3 cells identified the most abundant mature RNAs in the chromatin fraction, and biological replicates identified the same RNAs as being the most abundant in different HeLa S3 NET-seq libraries. On the basis of these sequencing results, we designed biotinylated DNA oligos complementary to the 3′ regions of the 20 most abundant mature RNAs in our NET-seq libraries ( Table 2) . To deplete abundant mature RNAs, these DNA oligos are hybridized to first-strand cDNA during library preparation; duplexes formed between the biotinylated oligos and their targets are removed by streptavidincoupled magnetic beads. The same set of depletion oligos has been successfully applied during NET-seq library preparations from HEK293T cells. The set of depletion oligos might need to be amended for other cell types, as chromatin-associated mature RNAs can vary among different cell and tissue types.
PCR amplification. Before high-throughput sequencing on an Illumina platform, the NET-seq library is amplified by a limited number of PCR cycles using an Illumina index forward primer and a NET-seq-specific reverse primer (oNTI231; Table 1 ). To avoid overamplification, the minimum number of PCR cycles required to obtain a NET-seq library needs to be determined for each library preparation (see Step 88 of the PROCEDURE and Fig. 3c for more information). We typically test between 6 and 12 PCR amplification cycles (Fig. 3c) . The NET-seq library is then amplified with the minimal amount of PCR cycles (Fig. 3d) .
Quality controls for library preparation. The human NET-seq library construction requires several enzymatic reactions, such as ligation, RT, circularization and PCR amplification (Fig. 1) . We have observed variations between different enzyme lots, and thus we suggest keeping track of the lot numbers for each enzyme. We also include a purified RNA oligonucleotide (oGAB11 ; Table  1 ) 24 sample, which is processed in parallel to the library sample (Steps 24-27, 30-69 and 80-88 of the PROCEDURE), as a control to monitor the success of each enzymatic reaction. In particular, we recommend using this control RNA oligonucleotide to determine the ligation efficiency. Ligation of the DNA linker to the 3′ end of the nascent RNA is one of the most critical steps in the NETseq protocol, as only nascent RNA molecules that ligate with the DNA linker are captured in the NET-seq library. To ensure a high sensitivity of the NET-seq approach and to minimize biases, the ligation efficiency should be at least 90% (Supplementary Fig. 1 ). After the DNA linker has been ligated to oGAB11, the ligation product can be used to monitor the success of first-strand cDNA synthesis by SuperScript III reverse transcriptase; if successful, a distinct band should be observed at ~100 nt. This oGAB11 cDNA can then be used to determine the circularization efficiency by the CircLigase. Alternatively, circularization efficiency can be monitored by circularizing the RT primer oLSC007 ( Table 1) . The circularized product migrates more slowly than the linear molecule, and it can be visualized by gel electrophoresis. oGAB11 cDNA also serves as a positive control during PCR amplification by the Phusion DNA polymerase. Fig. 2 and supplementary Fig. 2) . We recommend using these Pol II-specific antibodies, as their CTD specificities have been extensively characterized 63 . Optionally, the membrane can also be probed with antibodies raised against the subcellular marker proteins GAPDH (cytoplasm), U1 snRNP70 (nucleoplasm) and histone 2B (chromatin). We recommend probing the subcellular fractions with these antibodies when a new cell type is used. Triton X-100 and 573 µl of RNase-free H 2 O. The volume will be enough to perform seven specific depletion experiments using two depletion reactions per sample. Store it at room temperature for several months. ! cautIon EDTA and Triton X-100 are irritants. Triton X-100 is harmful and hazardous to the environment. Handle solutions containing Triton X-100 with care and dispose of waste according to institutional regulations. DNA loading buffer (6×) Dissolve 6 g of sucrose and 30 mg of Orange G in 20 ml of RNase-free H 2 O. Bring the buffer to a final volume of 25 ml with RNase-free H 2 O. Store it, protected from light, at room temperature for up to 1 year. Gel staining solution To stain one TBE or TBE-urea gel, add 5 µl of SYBR Gold nucleic acid gel stain to 50 ml of 1× TBE buffer and mix. Prepare this solution immediately before use, and store it, protected from light, at room temperature until required. ! cautIon SYBR Gold nucleic acid gel stain is flammable. Nucleic acid stains are usually mutagenic. Use personal protective equipment when handling nucleic acid gel stains and dispose of waste according to institutional regulations.
MaterIals

REAGENTS
proceDure Quantitative purification of rna polymerase by cell fractionation • tIMInG 45 min  crItIcal Cell fractionation has been optimized for HeLa S3 and HEK293T cells. If you are using other cell types, protocol optimizations might be required.  crItIcal Cell fractionation is performed on ice or at 4 °C, with buffers freshly prepared on the same day. All buffers are precooled on ice before use. Use RNase-free reagents and equipment. 1| Grow HeLa S3 or HEK293T cells in a 15 × 2.5 cm dish in DMEM containing 10% (vol/vol) FBS, 100 U/ml penicillin and 100 µg/ml streptomycin until they are 90% confluent.  crItIcal step Grow human cells according to the Cell Culture Guidelines of the Encyclopedia of DNA Elements (ENCODE) project (https://www.encodeproject.org/documents/60b6b535-870f-436b-8943-a7e5787358eb/). This includes keeping track of the growth time, passage number and cell density.
2|
Wash the cells twice with 10 ml of PBS buffer.  crItIcal step Unless otherwise stated, perform all washing steps on ice. A typical wash takes <1 min.
3| Scrape cells into 1 ml of PBS buffer.
4| Determine the cell number by counting using a cell counter (see Equipment for details). Use 1×10 7 cells as input for each cell fractionation. In addition to the experimental sample, also process in parallel a control for western blot analysis (described in Box 1; see also Figs. 1,2 and supplementary Fig. 2 ).
5| Wash each sample of 1× 10 7 cells with 10 ml of PBS.
6|
Collect cells by centrifugation at 500g for 2 min at 4 °C.
7|
Remove the supernatant by aspiration.  crItIcal step It is important to remove the supernatant completely at this step. If the supernatant is not completely removed, the cytoplasmic lysis buffer (Step 8) will be diluted, which affects the cell lysis efficiency. 8| Add 200 µl of cytoplasmic lysis buffer and transfer it to an RNase-free 1.5-ml microcentrifuge tube. By using a cut 1,000-µl pipette tip, pipette the sample up and down ten times.
9|
Incubate the cell lysate on ice for 5 min.
10| By using a cut 1,000-µl pipette tip, layer the cell lysate onto 500 µl of sucrose buffer.
11|
Collect cell nuclei by centrifugation at 16,000g for 10 min at 4 °C.
12|
Remove the supernatant.  crItIcal step The supernatant represents the cytoplasmic fraction. The cytoplasmic fraction is only retained for the western blot control sample (Box 1).
13|
Wash nuclei with 800 µl of nuclei wash buffer.
14|
Collect washed nuclei by centrifugation at 1,150g for 1 min at 4 °C.  crItIcal step To remove cytoplasmic mature RNAs, it is important to remove the supernatant completely.
15| Add 200 µl of glycerol buffer. By using a cut 1,000-µl tip, resuspend the washed nuclei by pipetting up and down.
Transfer the suspension to a new 1.5-ml RNase-free microcentrifuge tube.
16|
Add 200 µl of nuclei lysis buffer, mix by pulsed vortexing and incubate the mixture on ice for 2 min.
17|
Centrifuge the mixture at 18,500g for 2 min at 4 °C.
18|
Remove the supernatant completely.  crItIcal step It is important to completely remove the supernatant containing nucleoplasmic RNAs. The nucleoplasmic fraction is retained only for the western blot control sample (Box 1).
19|
Resuspend the chromatin in 50 µl of chromatin resuspension solution.  crItIcal step It is important to resuspend the sticky chromatin pellet before the preparation of the nascent RNA. This step increases the RNA yield. This step is performed for the experimental sample, as well as for the control sample. The experimental sample is used for the preparation of the nascent RNA (Step 20). The control sample is used for the western blot analysis, as described in Box 1.
preparation of nascent rna • tIMInG 1 h 20| Add 700 µl of QIAzol lysis reagent (part of miRNeasy mini kit, Qiagen) to the resuspended chromatin from Step 19.
21|
Mix thoroughly by slowly pipetting up and down using a 1-ml syringe with a 22G needle. Alternatively, the chromatin pellet can also be solubilized by gentle vortexing. ! cautIon Be aware that the QIAzol lysis reagent contains phenol. Handle solutions with care and according to institutional regulations.  crItIcal step Mix very carefully until the solution is homogeneous. Mix it slowly to avoid spilling the sample.
22|
Prepare RNA using the miRNeasy mini kit according to the manufacturer's instructions, including the optional on-column DNase treatment using the RNase-free DNase set (Qiagen). 25| Prepare DNA linker ligation mix for each RNA sample and for oGAB11 in 0.2-ml RNase-free PCR tubes, as described in the table below. Prepare three ligation reactions per RNA sample and for the oGAB11 control; the RNA input per ligation reaction is 1 µg.  crItIcal step Before adding the truncated T4 RNA ligase 2, it is important to mix the ligation reaction until it is homogeneous. Next, add the ligase and mix again. Incompletely mixed samples will negatively affect the ligation efficiency. 
29|
Fragment the RNA at 95 °C in a thermal cycler for the appropriate time.  crItIcal step The fragmentation time needs to be adjusted whenever a new batch of alkaline fragmentation solution is applied. An overfragmentation or underfragmentation of the nascent RNA pool can lead to systematic biases. In a typical experiment RNA is fragmented between 10 and 40 min at 95 °C (Fig. 3a) . The optimal fragmentation time is when most RNA molecules are in the required size range, usually between 35 and 100 nt (Fig. 3a, lane 6 ). 
30|
33|
Remove the supernatant and wash the pellet with 750 µl of 80% (vol/vol) ice-cold ethanol.
34|
Spin the sample at 20,000g for 2 min at 4 °C, and then remove the supernatant.
35| Air-dry the RNA pellet for 10 min at room temperature.
36|
Resuspend the RNA pellet in 10 µl of RNase-free H 2 O. Add 10 µl of 2× TBU denaturing sample buffer to each RNA sample and mix it.
37|
Prepare the RNA control ladder and the oGAB11 control. Add 1.0 µl of RNA control ladder or oGAB11 to 9 µl of RNase-free H 2 O. Add 10 µl of 2× TBU denaturing sample buffer to each control sample and mix it. 41| Stain the gel in 50 ml of gel staining solution for 5 min at room temperature on a shaker. Protect the gel from light during staining by the use of a black gel box.
42|
Visualize the fragmented RNA and the oGAB11 ligation control under blue or UV light ( Fig. 3a and supplementary  Fig. 1 ). For the fragmented RNA, excise the region between 35 and 100 nt (Fig. 3a) . For the oGAB11 ligation control, excise the narrow band at ~55 nt (supplementary Fig. 1, lane 4) .
43|
Extract the RNA from the gel slice by rapid gel extraction, as described in Box 2.
44| Precipitate RNA by adding 2 µl of 15 mg/ml GlycoBlue and 50 µl of 3 M sodium acetate (pH 5.5). Mix well. Add 750 µl of isopropanol and mix well. Incubate the precipitations at −80 °C for ≥1 h.  pause poInt The RNA precipitations can be stored at −80 °C overnight.
45| Recover the RNA as described in Steps 32-35.
46|
Resuspend the size-selected RNA and the oGAB11 ligation control in 10 µl of precooled RNase-free H 2 O.
rt • tIMInG 4 h (plus overnight and ~1 h the next day) 47|
Prepare the RT reaction mix tabulated below in a 0.2-ml RNase-free PCR tube and store it on ice. 
54|
Neutralize the reaction by adding 1.8 µl of 1 N HCl; mix well and put the reaction on ice.
55| Add 20 µl of 2× TBU denaturing sample buffer to each cDNA sample and the oGAB11 cDNA control, and then mix.
56|
Prepare the DNA control ladder. Add 1.0 µl of DNA control ladder to 9 µl of RNase-free H 2 O. Add 10 µl of 2× TBU denaturing sample buffer to each cDNA sample and mix.
57| Denature the cDNA sample, oGAB11 cDNA control and DNA control ladder for 3 min at 95 °C in a Thermomixer. Cool the samples on ice for 3 min. 59| Separate the cDNA sample, the oGAB11 cDNA control and the DNA ladder by PAGE at 200 V for 65 min.
60|
Stain the gel in 50 ml of gel staining solution for 5 min at room temperature on a shaker. Protect the gel from light during staining by the use of a black gel box.
61|
Visualize the gel under blue/UV light and excise the cDNA between 85 and 160 nt (Fig. 3b) .
? trouBlesHootInG 62| Extract the cDNA from the gel slice by rapid gel extraction, as described in Box 2. Combine eluates from two lanes (expected volume ~400 µl), add 25 µl of 5 M NaCl and mix. 72| Prepare Dynabeads MyOne streptavidin C1 (10 mg/ml) for specific depletion, as described in Box 3.
73| Transfer 10 µl of depletion reaction directly from the 0.2-ml PCR tube in the thermal cycler (from Step 71) to the washed and equilibrated beads in the Thermomixer. Immediately mix by pipetting.
74|
Incubate the mixture in the Thermomixer for 15 min at 37 °C with mixing at 1,000 r.p.m.
75|
Transfer the tubes from the Thermomixer into a magnetic rack and leave them for 1 min. Transfer the supernatant into a new 1.5-ml microcentrifuge tube.  crItIcal step The supernatant needs to be transferred carefully. Any remaining magnetic beads in the supernatant will have a negative impact on subsequent steps. 86| Separate the PCR products and the DNA control ladder by TBE gel electrophoresis on an 8% (wt/vol) TBE gel at 180 V for 55 min.
76|
87| Stain the gel in 50 ml of gel staining solution for 5 min at room temperature on a shaker. Protect the gel from light during staining by the use of a black gel box.
88|
Visualize the gel under blue/UV light and identify the optimal PCR amplification cycle for each cDNA sequencing library (Fig. 3c) . The NET-seq library runs at ~150 nt (Fig. 3c) . The optimal PCR amplification cycle is characterized by a clear band at ~150 nt and the absence of PCR products at the higher-molecular-weight range (Fig. 3c, lane 3) . ? trouBlesHootInG 89| Perform four PCR amplification reactions per sample with the optimal amplification cycle, as described in Steps 80-88. The oGAB11 control sample is not subjected to Steps 89-105.
? trouBlesHootInG 90| For each sample, excise the band that contains the PCR product from the gel (Fig. 3d) .  crItIcal step Excise the broad band at ~150 nt. Avoid contamination from the lower band that runs at ~120 nt, representing PCR product from empty circles (Fig. 3d, brown asterisk) . Empty circles are circularized cDNA molecules that arise from unextended RT primers, and hence they do not contain any information about the original nascent RNA. 91| Pierce the bottom of a 0.5-ml DNase-free microcentrifuge tube with a 21G needle.
92|
Put the pierced 0.5-ml tube in a 1.5-ml DNase-free microcentrifuge tube.
93|
Place the gel slices into the inner pierced 0.5-ml tube.
94|
Centrifuge the tube at 20,000g for 4 min at room temperature.
95|
Add 670 µl of DNA soaking buffer and mix.
96|
Incubate the tube at room temperature at 1,500 r.p.m. overnight in a Thermomixer.
97| By using a cut 1,000-µl pipette tip, transfer the gel slurry into a microcentrifuge tube filter.
98|
Centrifuge at 20,000g for 3 min at room temperature. Transfer the eluate to a new 1.5-ml microcentrifuge tube. 103| Use 1 µl of the diluted NET-seq library for quantification with the Qubit fluorometer using the Qubit dsDNA HS assay kit. Prepare the sample and perform the measurement according to the manufacturer's protocol.
104| Use 1 µl of the diluted NET-seq library for characterization on the Agilent Bioanalyzer; use the high-sensitivity DNA analysis kit according to the manufacturer's instructions.
105|
Sequence the human NET-seq library from the 3′ end on the Illumina platform using oLSC006 (table 1) as a custom sequencing primer. Perform sequencing according to the manufacturer's instructions. NET-seq libraries are typically sequenced on MiSeq, HiSeq or NextSeq next-generation sequencing platforms. A reasonable coverage is obtained with 100-200 million reads. A brief guide to the bioinformatics analysis of human NET-seq data is given in Box 4. A more detailed description of the computational analysis of human NET-seq data can also be found in the supplemental information of the original human NET-Seq publication 29 .
? trouBlesHootInG Troubleshooting advice can be found in table 3.
• Strong PCR band at ~120 nt on an 8% (wt/vol) TBE gel (Fig. 3c,d) PCR product that originates from empty circles. Empty circles arise from unextended RT primers that get circularized by the CircLigase enzyme Precisely excise the RT product (Step 61) and use less RT primer Precisely excise the final PCR product at around 150 nt (Fig. 3d (Fig. 3a) . The cDNA that is obtained upon RT (PROCEDURE Steps 47-61) runs between 80 and 160 nt, as observed by PAGE (Fig. 3b) . Gel electrophoresis of the PCR product after the final amplification (PROCEDURE Steps 80-89) reveals a broad band at ~150 nt (Fig. 3c,d ). The total yield of a typical NET-seq library from HeLa S3 and HEK293T cells is usually 20-30 ng, as determined by Qubit fluorometer (PROCEDURE Step 103) and Bioanalyzer (PROCEDURE Step 104) measurements. The average fragment length of the human NET-seq library is ~150 nt (Fig. 4) . High-throughput sequencing of a typical NET-seq library (PROCEDURE Step 105 and Box 4) obtained from HeLa S3 cells has the following characteristics: ~50% of the sequencing reads map uniquely to the annotated human reference genome. Of those reads, 76% align to Pol IItranscribed genes, 15% align to Pol I-transcribed genes (also included are reads that map to spacer regions of The NET-seq library was generated from 3 µg of RNA obtained from HeLa S3 cells. Approximately 1.1 ng of the final NET-seq library was loaded onto a high-sensitivity DNA microfluidic chip. The profile shows a prominent peak around 150 nt (violet arrow) and a smaller peak around 120 nt (green arrow). The less prominent peak corresponds to background that arises from unextended RT primer leading to a 119-nt PCR product (see also Fig. 3c,d ). This background DNA also results in sequencing data. However, these sequencing reads will contain sequences of the 3′ and 5′ linker regions that are part of the RT primer and are computationally removed. The background DNA should be lower than 10%, as compared with the amount of the NET-seq library. The peak at 35 nt represents the manufacturer's internal standard. a.u., arbitrary units. 29 . HENMT1, HEN1 methyltransferase homolog 1; PRPF38B, pre-mRNA processing factor 38B; FNDC7, fibronectin type III domain containing 7; STXBP3, syntaxin binding protein 3.
